Edistride Europäische Union - Deutsch - EMA (European Medicines Agency)

edistride

astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Forxiga Europäische Union - Deutsch - EMA (European Medicines Agency)

forxiga

astrazeneca ab - dapagliflozin-propandiol-monohydrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogen bei diabetes verwendet - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. zusätzlich zu anderen arzneimitteln für die behandlung von typ-2-diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 und 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Qtern Europäische Union - Deutsch - EMA (European Medicines Agency)

qtern

astra zeneca ab - saxagliptin, dapagliflozin propandiol monohydrat - diabetes mellitus, type 2; diabetes mellitus; nutritional and metabolic diseases; metabolic diseases; glucose metabolism disorders - drogen bei diabetes verwendet - qtern, fest-dosis-kombination von saxagliptin und dapagliflozin, ist indiziert bei erwachsenen im alter von 18 jahren und älter mit typ-2-diabetes mellitus:verbesserung der glykämischen kontrolle bei metformin und/oder sulphonylurea (su) und eine der monocomponents von qtern bieten keine adäquaten glykämischen kontrolle,wenn schon die behandlung mit der freien kombination von dapagliflozin und saxagliptin. (siehe abschnitt 4. 2, 4. 4, 4. 5 und 5. 1 für verfügbare daten über kombinationen untersucht.